FOR IMMEDIATE RELEASE

Contact:
Michelle Mathias
RMS Medical Products
Phone:  845-469-2042
Fax:  845-469-5518
mmathias@rmsmedpro.com
www.rmsmedicalproducts.com

Repro Med Systems, Inc. Clarifies Product Standing

CHESTER, NY / April 7, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) issued a statement today concerning receipt of an FDA “Warning Letter” which may have created uncertainty as to the status of the company’s FREEDOM® System devices.

On February 29, 2016, RMS received a Warning Letter from the FDA as a result of a routine FDA GMP (Good Manufacturing Practices) inspection in June 2015, which was extended to three weeks due a trade complaint the agency received. This Warning Letter has been misrepresented in media reports and misunderstood by the industry.

“The FDA identifies a warning letter as an advisory document, not an enforcement action. RMS submitted a timely, comprehensive response, currently being reviewed by the FDA,” said Andy Sealfon, RMS Medical Products’ CEO.

Specifically, in the FDA’s Regulatory Procedures manual (RPM Chapter 4 ), an FDA warning letter is defined as: “… informal and advisory … does not commit FDA to taking enforcement action … FDA does not consider Warning Letters to be final agency action …”

RMS Medical Products has continuously delivered premium infusion products for the past 25 years. Caregivers’ confidence in the products is the reason why the FREEDOM® System is the first choice for subcutaneous immune globulins. RMS incorporates feedback from all health care professionals and patients to continually improve products. That’s why FREEDOM® System is the preferred choice of products for subcutaneous immune globulin (SClg) for 90%+ of the market.

RMS Medical Products has been a pioneer in SClg infusions since 2003 even before the first commercial subcutaneous immune globulin was available, and has been pro-active in supporting minimum pain and redness with consistent and comfortable results.

Sealfon assures patients that, despite what they may be hearing or reading the FDA letter has no impact on the availability and unsurpassed quality of RMS products.

“Patients already know from experience that our products are accurate, consistent, safe and effective for their administrations,” he said. “We will continue to supply the FREEDOM® System and HlgH-Flo™ Needle Sets with the same quality and performance that our users have come to expect. By actively listening to user feedback and investing in a new wave of innovations, RMS will exceed all expectations by continuing to be a leading pioneer. Innovation is more than product
development; it is about empowering health care to improve the quality of life and home infusion processes together. At RMS, we always put the patient first!"

Sealfon is making himself available to answer any questions, to work with you on any issues or problems you have, and to respond to any complaint about the performance of our products. He can be reached at (845) 469-2042.

**About RMS Quality Control**

RMS works daily with patient safety in mind, as evidenced by their voluntary market withdrawal of a limited number of products identified on February 24th due to a potential defect which was found in the packaging received from a supplier. The withdrawal process of this low-risk defect has been effective and is nearly complete. If you have any questions, call RMS customer service at (800) 642-9600.

**About RMS Medical Products**

RMS Medical Products manufactures medical products used for infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge™ Syringe Infusion Pumps, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.

The company's website is [www.rmsmedicalproducts.com](http://www.rmsmedicalproducts.com).

*This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes", "belief", "expects", "intends", "anticipates", "will", or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.*